Revenue grew 5.5% year-over-year in Q2 2026, with adjusted EPS up 8% and strong free cash flow. Life Sciences and Diagnostics led segment growth, while Biotechnology moderated. Full-year guidance anticipates mid-single-digit core sales growth and continued margin discipline.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.